Transcriptome Sequencing to Explore the Mechanism of Qiwei Baizhu San in Treating T2DM.

Objective: This study aims to explore the mechanism of Qiwei Baizhu San in treating T2DM by high-throughput transcriptome sequencing. Methods: T2DM rats were made by STZ + high fat and high sugar diet. The rats were divided into control group, model group and Qiwei Baizhu San treatment group. Three rats from each of the three groups were taken for transcriptome sequencing. The disease targets of T2DM were searched through Genecards and other databases, and the PPI network analysis and GO and KEGG enrichment analysis were carried out after crossing with the model-blank group differential genes of transcriptome sequencing data The intersection target was intersected with the gene of Qiwei Baizhu San reversing T2DM in transcriptome sequencing to obtain the target of Qiwei Baizhu San for treating T2DM. PPI network analysis and GO and KEGG enrichment analysis were carried out, and the mechanism of Qiwei Baizhu San for treating T2DM was explored through network pharmacology and molecular docking technology. Results: 13891 T2DM related targets were retrieved, and 295 overlapping targets were obtained after crossing with 507 differential genes sequenced by transcriptome. The PPI network was drawn to obtain LCk, CD8, CD28 and other key T2DM pathogenesis targets. A total of 56 key therapeutic targets were obtained by intersecting 295 intersection targets with the genes of Qiwei Baizhu San reversing T2DM in transcriptome sequencing, and key genes such as PTPRC, IRF4 and BTk were obtained by PPI network analysis. The results of molecular docking showed that the active ingredient of Qiwei Baizhu San had good binding with the therapeutic target of T2DM. Conclusion: Qiwei Baizhu San can obviously improve T2DM, and its treatment has the characteristics of multi-target and multi-channel, which provides a theoretical basis for the further study of Qiwei Baizhu San.